Please contact us for more information or to learn if you are eligible to participate.
This phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair.
Edgar Lopez Pacheco
National Cancer Institute (NCI)
Type of Trial